Cargando…

Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency

BACKGROUND: Dual-release hydrocortisone (DR-HC) improves metabolism in patients with adrenal insufficiency. The aims of this study were to compare the cardiovascular and metabolic effects of conventional glucocorticoids (GCs) vs. DR-HC and of high vs. low doses of GCs, after 48 months of observation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guarnotta, V, Di Stefano, C, Santoro, A, Ciresi, A, Coppola, A, Giordano, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599082/ https://www.ncbi.nlm.nih.gov/pubmed/31252397 http://dx.doi.org/10.1530/EC-19-0176

Ejemplares similares

Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: a real-life study
por: Guarnotta, Valentina, et al.
Publicado: (2019)

Tissue Glucocorticoid Metabolism in Adrenal Insufficiency: A Prospective Study of Dual-release Hydrocortisone Therapy
por: Dineen, Rosemary A, et al.
Publicado: (2023)

Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency
por: Bioletto, Fabio, et al.
Publicado: (2023)

Early Metabolic Benefits of Switching Hydrocortisone to Modified Release Hydrocortisone in Adult Adrenal Insufficiency
por: Bannon, Christopher A. M., et al.
Publicado: (2021)

A Prospective Cross-Over Study of Tissue Glucocorticoid Metabolism in Patients With Adrenal Insufficiency: The Effects of Dual-Release Hydrocortisone Therapy
por: Dineen, Rosemary Anne, et al.
Publicado: (2021)

Long-term outcomes of conventional and novel steroid replacement therapy on bone health in primary adrenal insufficiency
por: Guarnotta, Valentina, et al.
Publicado: (2022)

Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency
por: Gasco, V., et al.
Publicado: (2022)

Metabolic Effects of Cortisone Acetate vs Hydrocortisone in Patients With Secondary Adrenal Insufficiency
por: Ekstrand, Elise, et al.
Publicado: (2020)

Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency
por: Nilsson, A G, et al.
Publicado: (2014)

SAT-391 Perioperative Glucocorticoid Therapy for Patients with Adrenal Insufficiency: Dosing Based on Hydrocortisone Pharmacokinetic Data
por: Rahhal, Marie-Noel, et al.
Publicado: (2019)

SAT-381 Cognitive Function and Quality of Sleep in Patients with Adrenal Insufficiency May Benefit by Therapy with Dual-Release Hydrocortisone
por: Krekeler, Clarissa, et al.
Publicado: (2019)

Prediction of diabetes mellitus induced by steroid overtreatment in adrenal insufficiency
por: Guarnotta, Valentina, et al.
Publicado: (2022)

Switching From Immediate-Release to Fractionated Dual-Release Hydrocortisone May Improve Metabolic Control and QoL in Selected Primary Adrenal Insufficiency Patients
por: Delle Cese, Francesca, et al.
Publicado: (2021)

Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia
por: Merke, Deborah P, et al.
Publicado: (2021)

Effects of the therapy shift from cortisone acetate to modified-release hydrocortisone in a group of patients with adrenal insufficiency
por: Frigerio, Sofia, et al.
Publicado: (2023)

Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study
por: Nilsson, Anna G, et al.
Publicado: (2017)

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report
por: Ciresi, A., et al.
Publicado: (2018)

Hydrocortisone malabsorption due to polyethylene glycols (Macrogol 3350) in a girl with congenital adrenal insufficiency
por: Stagi, Stefano, et al.
Publicado: (2014)

Exenatide Alters Absorption of Hydrocortisone in a Diabetic Patient With Panhypopituitarism: Iatrogenic Adrenal Insufficiency
por: Fujita, Yukari, et al.
Publicado: (2013)

Prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency
por: Quinkler, Marcus, et al.
Publicado: (2016)

SUN-358 Dual Release Hydrocortisone as a New Treatment for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
por: Simeoli, Chiara, et al.
Publicado: (2019)

Modified-Release and Conventional Glucocorticoids and Diurnal Androgen Excretion in Congenital Adrenal Hyperplasia
por: Jones, Christopher M., et al.
Publicado: (2016)

Recovery of Adrenal Function in Patients with Glucocorticoids Induced Secondary Adrenal Insufficiency
por: Baek, Jong Ha, et al.
Publicado: (2016)

Novel insights into glucocorticoid replacement therapy for pediatric and adult adrenal insufficiency
por: Oprea, Alina, et al.
Publicado: (2019)

Improved salivary cortisol rhythm with dual-release hydrocortisone
por: Ceccato, Filippo, et al.
Publicado: (2018)

Glucocorticoid-induced adrenal insufficiency: an uncommon cause of hypercalcaemia
por: De Silva, S D N, et al.
Publicado: (2022)

BclI polymorphism of the glucocorticoid receptor and adrenal crisis in primary adrenal insufficiency
por: Zopf, Kathrin, et al.
Publicado: (2017)

In Vitro Evaluation of Cocoa Pod Husk Pectin as a Carrier for Chronodelivery of Hydrocortisone Intended for Adrenal Insufficiency
por: Adi-Dako, Ofosua, et al.
Publicado: (2017)

COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency
por: Isidori, A. M., et al.
Publicado: (2020)

Hepatic Steatosis Index in Acromegaly: Correlation with Insulin Resistance Regardless of the Disease Control
por: Ciresi, Alessandro, et al.
Publicado: (2018)

The metabolic outcomes of growth hormone treatment in children are gender specific
por: Ciresi, Alessandro, et al.
Publicado: (2018)

The use of prednisolone versus dual-release hydrocortisone in the treatment of hypoadrenalism
por: Choudhury, Sirazum, et al.
Publicado: (2021)

Novel HPLC Analysis of Hydrocortisone in Conventional and Controlled-Release Pharmaceutical Preparations
por: Adi-Dako, Ofosua, et al.
Publicado: (2017)

Empiric Determination of the Daily Glucocorticoid Replacement Dose in Adrenal Insufficiency
por: Caetano, Celina M, et al.
Publicado: (2020)

Adrenal Insufficiency and Glucocorticoid Use During the COVID-19 Pandemic
por: Almeida, Madson Q., et al.
Publicado: (2020)

Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection
por: Isidori, Andrea M, et al.
Publicado: (2020)

Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life
por: Mongioì, L M, et al.
Publicado: (2017)

A Prospective Study of Children Aged 0–8 Years with CAH and Adrenal Insufficiency Treated with Hydrocortisone Granules
por: Neumann, Uta, et al.
Publicado: (2020)

Improved Cardiovascular and Cardiometabolic Risk in Patients With Type 1 Diabetes and Autoimmune Polyglandular Syndrome Switched From Glargine to Degludec Due to Hypoglycaemic Variability
por: Guarnotta, Valentina, et al.
Publicado: (2018)

Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review
por: Joseph, Rebecca M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_u1j0b027mh639fa8f33k5bm2o1